TherapeuticsMD (NASDAQ: TXMD) reported Q2 EPS of ($0.11), in-line with the analyst estimate of ($0.11). Revenue for the quarter came in at $23 million versus the consensus estimate of $22.11 million.

For earnings history and earnings-related data on TherapeuticsMD (TXMD) click here.